全文获取类型
收费全文 | 21391篇 |
免费 | 1135篇 |
国内免费 | 155篇 |
专业分类
耳鼻咽喉 | 224篇 |
儿科学 | 446篇 |
妇产科学 | 205篇 |
基础医学 | 2414篇 |
口腔科学 | 420篇 |
临床医学 | 1511篇 |
内科学 | 6008篇 |
皮肤病学 | 458篇 |
神经病学 | 1601篇 |
特种医学 | 796篇 |
外科学 | 3997篇 |
综合类 | 47篇 |
预防医学 | 495篇 |
眼科学 | 395篇 |
药学 | 1171篇 |
中国医学 | 49篇 |
肿瘤学 | 2444篇 |
出版年
2024年 | 17篇 |
2023年 | 169篇 |
2022年 | 324篇 |
2021年 | 689篇 |
2020年 | 373篇 |
2019年 | 469篇 |
2018年 | 641篇 |
2017年 | 425篇 |
2016年 | 589篇 |
2015年 | 553篇 |
2014年 | 776篇 |
2013年 | 897篇 |
2012年 | 1427篇 |
2011年 | 1656篇 |
2010年 | 918篇 |
2009年 | 819篇 |
2008年 | 1345篇 |
2007年 | 1400篇 |
2006年 | 1352篇 |
2005年 | 1421篇 |
2004年 | 1454篇 |
2003年 | 1319篇 |
2002年 | 1215篇 |
2001年 | 226篇 |
2000年 | 198篇 |
1999年 | 226篇 |
1998年 | 249篇 |
1997年 | 237篇 |
1996年 | 171篇 |
1995年 | 144篇 |
1994年 | 154篇 |
1993年 | 114篇 |
1992年 | 103篇 |
1991年 | 91篇 |
1990年 | 68篇 |
1989年 | 55篇 |
1988年 | 51篇 |
1987年 | 57篇 |
1986年 | 48篇 |
1985年 | 29篇 |
1984年 | 35篇 |
1983年 | 21篇 |
1982年 | 23篇 |
1981年 | 18篇 |
1980年 | 17篇 |
1979年 | 16篇 |
1978年 | 12篇 |
1976年 | 11篇 |
1975年 | 14篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
951.
Robert J. Motzer MD Bernard Escudier MD Saby George MD Hans J. Hammers MD PhD Sandhya Srinivas MD Scott S. Tykodi MD PhD Jeffrey A. Sosman MD Elizabeth R. Plimack MD Giuseppe Procopio MD David F. McDermott MD Daniel Castellano MD Toni K. Choueiri MD Frede Donskov MD PhD Howard Gurney MD Stéphane Oudard MD Martin Richardet MD PhD Katriina Peltola MD PhD Ajjai S. Alva MD Michael Carducci MD John Wagstaff MD Christine Chevreau MD Satoshi Fukasawa MD Yoshihiko Tomita MD PhD Thomas C. Gauler MD Christian K. Kollmannsberger MD Fabio A. Schutz PhD James Larkin MD PhD David Cella PhD M. Brent McHenry PhD Shruti Shally Saggi BEng Nizar M. Tannir MD 《Cancer》2020,126(18):4156-4167
952.
953.
Atsushi Hata Takahiro Nakajima Keisuke Matsusaka Masaki Fukuyo Junichi Morimoto Takayoshi Yamamoto Yuichi Sakairi Bahityar Rahmutulla Satoshi Ota Hironobu Wada Hidemi Suzuki Hisahiro Matsubara Ichiro Yoshino Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(2):388-399
954.
Takuya Nakagawa Keisuke Matsusaka Kiyoshi Misawa Satoshi Ota Masaki Fukuyo Bahityar Rahmutulla Naoki Kunii Daiju Sakurai Toyoyuki Hanazawa Hisahiro Matsubara Yoshitaka Okamoto Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(9):2460-2474
While the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing in these two decades, primarily due to human papillomavirus (HPV), stratification of OPSCC into molecular subgroups showing different clinicopathological features has not been fully investigated. We performed DNA methylome analysis using Infinium 450k for 170 OPSCC cases, including 89 cases in our cohort and 81 cases reported by The Cancer Genome Atlas, together with targeted exon sequencing analysis. We stratified OPSCC by hierarchical clustering analysis using methylome data. Methylation levels of classifier markers were validated quantitatively using pyrosequencing, and area under the curve (AUC) values of receiver operating characteristics (ROC) curves were calculated. OPSCC was stratified into four epigenotypes: HPV(+) high-methylation (OP1), HPV(+) intermediate-methylation (OP2), HPV(−) intermediate-methylation (OP3) and HPV(−) low-methylation (OP4). Ten methylation marker genes were generated: five to classify HPV(+) cases into OP1 and OP2, and five to classify HPV(−) cases into OP3 and OP4. AUC values of ROC curves were 0.969 and 0.952 for the two marker panels, respectively. While significantly higher TP53 mutation and CCND1 copy number gains were observed in HPV(−) than in HPV(+) groups (p < 0.01), no significant difference of genomic aberrations was observed between OP1 and OP2, or OP3 and OP4. The four epigenotypes showed significantly different prognosis (p = 0.0006), distinguishing the most favorable OPSCC subgroup (OP1) among generally favorable HPV(+) cases, and the most unfavorable OPSCC subgroup (OP3) among generally unfavorable HPV(−) cases. HPV(+) and HPV(−) OPSCC are further divided into distinct DNA methylation epigenotypes, showing significantly different prognosis. 相似文献
955.
956.
Kee Thai Yeo Ju Lee Oei Daniele De Luca Georg M. Schmölzer Robert Guaran Pamela Palasanthiran Kishore Kumar Giuseppe Buonocore Jeanie Cheong Louise S. Owen Satoshi Kusuda Jennifer James Gina Lim Ankur Sharma Sabita Uthaya Christopher Gale Elizabeth Whittaker Cheryl Battersby Neena Modi Mikael Norman Lars Naver Eric Giannoni Yenge Diambomba Prakeshkumar S. Shah Luigi Gagliardi Michael Harrison Shakti Pillay Abdullah Alburaey Yuan Yuan Huayan Zhang 《Acta paediatrica (Oslo, Norway : 1992)》2020,109(11):2192-2207
957.
Yutaka Fujioka Nobuhiro Hata Ryusuke Hatae Satoshi O. Suzuki Yuhei Sangatsuda Yukiko Nakahara Masahiro Mizoguchi Koji Iihara 《Neuropathology》2020,40(1):99-103
Diffuse midline glioma, H3 K27M mutant arises from midline structures of the central nervous system and predominately affects pediatric patients. However, this disease entity was only recently established, and the clinical phenotypic spectrum remains largely unclear. We herein report a rare case of diffuse midline glioma, H3 K27M mutant with an unusual distribution in an elderly woman who presented with a diffuse glioma that invaded both sides of the thalami, and left hippocampus and frontoparietal lobes, thus mimicking a hemispheric malignant glioma. A biopsy of the lobular lesion led to a molecular diagnostic confirmation of diffuse midline glioma, H3 K27M mutant. The patient received concurrent bevacizumab and temozolomide therapy with radiation therapy and survived for 30 months. This case highlights the possibility that a glioma with cerebral hemispheric spread in an elderly patient may harbor the H3 K27M mutation. 相似文献
958.
Shoko Sadashima Satoshi O. Suzuki Hironori Haruyama Nobutaka Mukae Yutaka Fujioka Nobuhiro Hata Masahiro Mizoguchi Keisuke Ishimatsu Akio Hiwatashi Toru Iwaki 《Neuropathology》2020,40(6):646-650
Here, we report a juvenile (18-year-old male) case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF mutation and a focal atypical feature resembling diffuse astrocytoma. The patient presented with refractory temporal lobe epilepsy. Subsequently, magnetic resonance imaging revealed a hyperintense lesion in the right temporal lobe on fluid attenuated inversion recovery images. The patient underwent right lateral temporal lobectomy and amygdalohippocampectomy. Histopathologically, the tumor showed isomorphic, diffuse, infiltrative proliferation of glial tumor cells and intense CD34 immunoreactivity. The tumor cells were immunonegative for isocitrate dehydrogenase 1 (IDH1) R132H and BRAF V600E. Notably, the tumor cells showed the lack of nuclear staining for α-thalassemia/mental retardation syndrome, X-linked (ATRX). In addition, the Ki-67 labeling index, using a monoclonal antibody MIB-1, was elevated focally at tumor cells with p53 immunoreactivity. Molecular analyses identified a BRAFA598T mutation, the first case reported in a glioma. BRAFA598T is predicted to result in loss of kinase action; however, inactive mutants can stimulate mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling through CRAF activation. Thus, according to the recent update of the consortium to inform molecular and practical approaches to central nervous system tumor taxonomy (cIMPACT-NOW update 4), our case is also compatible with diffuse glioma with the mitogen-activated protein kinase (MAPK) pathway alteration. Thorough immunohistochemical and molecular studies are necessary for diagnosis of epilepsy-associated, diffuse gliomas. Partial resemblance in histopathological and molecular genetic features to diffuse astrocytoma also calls for attention. 相似文献
959.
960.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献